论文部分内容阅读
目的探讨X线修复交叉互补基因1(XRCC1)与接受含铂方案化疗的晚期非小细胞肺癌(NSCLC)患者的近期疗效的关系。方法经病理确诊的晚期NSCLC患者62例,接受含铂方案化疗至少2个周期后评价疗效。采用TaqMan探针FQ-PCR法和直接测序法对患者外周血XRCC1第399位密码子进行多态性分析,分析各基因型与晚期NSCLC患者近期疗效及不良反应的的相关性。结果 XRCC1 399至少携带一个Gln等位基因携带者的疗效不如Arg等位基因携带者(14.81%vs.42.86%)(P<0.05)。XRCC1不同基因型与化疗不良反应无明显相关性。结论 XRCC1 399多态性与NSCLC患者对铂类药物化疗的敏感性相关。
Objective To investigate the relationship between XRCC1 and the short-term efficacy of advanced non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy. Methods Totally 62 patients with advanced NSCLC diagnosed by pathology were evaluated after at least 2 cycles of platinum-containing chemotherapy. The polymorphism of codon 399 of XRCC1 in peripheral blood of patients was analyzed by TaqMan probe FQ-PCR and direct sequencing. The correlation between each genotype and the short-term efficacy and adverse reactions of patients with advanced NSCLC was analyzed. Results XRCC1 399 had at least one allele of Gln allele with less effective than Arg allele (14.81% vs 42.86%) (P <0.05). There was no significant correlation between different genotypes of XRCC1 and adverse reactions of chemotherapy. Conclusion The polymorphism of XRCC1 399 is associated with the sensitivity of NSCLC patients to platinum chemotherapy.